

are working together as CALFED to provide policy direction and oversight for the process.

One area of Bay-Delta management includes the establishment of a joint State-Federal process to develop long-term solutions to problems in the Bay-Delta system related to fish and wildlife, water supply reliability, natural disasters, and water quality. The intent is to develop a comprehensive and balanced plan which addresses all of the resource problems. This effort, the CALFED Bay-Delta Program (Program), is being carried out under the policy direction of CALFED. The Program is exploring and developing a long-term solution for a cooperative planning process that will determine the most appropriate strategy and actions necessary to improve water quality, restore health to the Bay-Delta ecosystem, provide for a variety of beneficial uses, and minimize Bay-Delta system vulnerability. A group of citizen advisors representing California's agricultural, environmental, urban, business, fishing, and other interests who have a stake in finding long term solutions for the problems affecting the Bay-Delta system has been chartered under the Federal Advisory Committee Act (FACA) as Advisory Council BDAC to advise CALFED on the program mission, problems to be addressed, and objectives for the Program. BDAC provides a forum to help ensure public participation, and will review reports and other materials prepared by CALFED staff. BDAC has established a subcommittee called the Ecosystem Roundtable to provide input on annual workplans to implement ecosystem restoration projects and programs.

Minutes of the meeting will be maintained by the Program, Suite 1155, 1416 Ninth Street, Sacramento, CA 95814, and will be available for public inspection during regular business hours, Monday through Friday within 30 days following the meeting.

Dated: September 4, 1998.

Roger Patterson,

Regional Director, Mid-Pacific Region.

[FR Doc. 98-24655 Filed 9-14-98; 8:45 am]

BILLING CODE 4310-94-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA #167F]

Controlled Substances: Revised Aggregate Production Quotas for 1998

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of final revised 1998 aggregate production quotas.

SUMMARY: This notice establishes revised 1998 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).

EFFECTIVE DATE: September 15, 1998.

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator of the DEA pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations.

On July 17, 1998, a notice of the proposed revised 1998 aggregate production quotas for certain controlled substances in Schedules I and II was published in the **Federal Register** (63 FR 38671). All interested parties were invited to comment on or object to these proposed aggregate production quotas on or before August 17, 1998.

Several companies commented that the revised aggregate production quotas for amphetamine, codeine (for conversion), desoxyephedrine (methamphetamine), dihydrocodeine, fentanyl, hydrocodone (for sale), meperidine, methadone (for sale), methadone intermediate, methylphenidate, morphine (for sale), morphine (for conversion), oxycodone (for sale), oxymorphone, pentobarbital, propiram, secobarbital, sufentanil, tetrahydrocannabinols, and thebaine were insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and for the establishment and maintenance of reserve stocks.

DEA has reviewed the involved companies' 1997 year-end inventories, their initial 1998 manufacturing quotas, 1998 export requirements and their actual and projected 1998 sales. Based on this data, the DEA has adjusted the revised 1998 aggregate production quotas for amphetamine, desoxyephedrine (methamphetamine), dihydrocodeine, fentanyl, meperidine, methadone (for sale), methadone

intermediate, morphine (for sale), morphine (for conversion), oxycodone (for sale), oxymorphone, pentobarbital, propiram, tetrahydrocannabinols and thebaine to meet the estimated medical, scientific, research and industrial needs of the United States.

Regarding codeine (for conversion), hydrocodone (for sale), methylphenidate, secobarbital and sufentanil, the DEA has determined that no adjustments of the aggregate production quotas are necessary to meet the 1998 estimated medical, scientific, research and industrial needs of the United States.

Therefore, under the authority vested in the Attorney General by Section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations, the Acting Deputy Administrator hereby orders that the revised 1998 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:

Basic class	Established revised 1998 quotas
SCHEDULE I	
2,5-Dimethoxyamphetamine	20,000,100
2,5-Dimethoxy-4-ethylamphetamine (DOET) ...	2
3-Methylfentanyl	14
3-Methylthiofentanyl	2
3,4-Methylenedioxyamphetamine (MDA)	25
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ...	30
3,4-Methylenedioxymethamphetamine (MDMA)	20
3,4,5-Trimethoxyamphetamine	2
4-Bromo-2,5-Dimethoxyamphetamine (DOB)	2
4-Bromo-2,5-Dimethoxyphenethylamine (2-CB)	2
4-Methoxyamphetamine	100,100
4-Methylaminorex	2
4-Methyl-2,5-Dimethoxyamphetamine (DOM)	2
5-Methoxy-3,4-Methylenedioxyamphetamine	2
Acetyl-alpha-methylfentanyl	2
Acetylmethadol	7
Allylprodine	2
Alpha-acetylmethadol	7
Alpha-ethyltryptamine	2
Alphameprodine	2
Alpha-methadol	2
Alpha-methylfentanyl	2
Alphaprodine	2

Basic class	Established revised 1998 quotas	Basic class	Established revised 1998 quotas
Alpha-methylthiofentanyl	2	Meperidine	10,111,000
Aminorex	7	Methadone (for sale)	5,975,000
Beta-acetylmethadol	2	Methadone (for conversion)	585,000
Beta-hydroxyfentanyl	2	Methadone Intermediate	8,939,000
Beta-hydroxy-3-methylfentanyl	2	Methamphetamine (for conversion)	723,000
Beta-methadol	2	Methylphenidate	14,442,000
Betaprodine	2	Morphine (for sale)	12,445,000
Bufotenine	2	Morphine (for conversion)	77,975,000
Cathinone	9	Nabilone	2
Codeine-N-oxide	2	Noroxymorphone (for sale)	25,000
Diethyltryptamine	2	Noroxymorphone (for conversion)	2,117,000
Difenoxin	16,000	Opium	615,000
Dihydromorphone	7	Oxycodone (for sale)	12,118,000
Dimethyltryptamine	2	Oxymorphone	198,000
Ethylamine Analog of PCP	5	Pentobarbital	19,501,000
Heroin	2	Phencyclidine	60
Hydroxypethidine	2	Phenmetrazine	2
Lysergic acid diethylamide (LSD)	57	Phenylacetone	10
Mescaline	7	Secobarbital	397,000
Methaqualone	17	Sufentanil	1,800
Methcathinone	11	Thebaine	17,695,000
Morphine-N-oxide	2		
N-Ethylamphetamine	7		
N-Hydroxy-3,4-Methylenedioxyamphetamine	4		
N,N-Dimethylamphetamine	7		
Noracymethadol	2		
Norlevorphanol	2		
Normethadone	7		
Normorphine	7		
Para-fluorofentanyl	2		
Pholcodine	2		
Propiram	412,800		
Psilocin	2		
Psilocybin	2		
Tetrahydrocannabinols	51,000		
Thiofentanyl	2		
Trimeperidine	2		
SCHEDULE II			
1-Phenylcyclohexylamine	15		
1-Piperidinocyclohexanecarbonitrile (PCC)	12		
Alfentanil	8,100		
Amobarbital	12		
Amphetamine	5,554,000		
Cocaine	550,100		
Codeine (for sale)	62,020,000		
Codeine (for conversion)	23,906,000		
Desoxyephedrine	1,184,000		
1,151,000 grams of levodesoxyephedrine for use in a non-controlled, non-prescription product and 33,000 grams for methamphetamine.			
Dextropropoxyphene	109,500,000		
Dihydrocodeine	141,000		
Diphenoxylate	1,600,000		
Ecgonine	651,000		
Ethylmorphine	12		
Fentanyl	228,000		
Glutethimide	2		
Hydrocodone (for sale)	16,314,000		
Hydrocodone (for conversion) ..	3,000,000		
Hydromorphone	766,000		
Isomethadone	12		
Levo-alpha-acetylmethadol (LAAM)	356,000		
Levomethorphan	2		
Levorphanol	15,000		

beneficial. Accordingly, the Acting Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

Dated: September 3, 1998.

Donnie R. Marshall,

Acting Deputy Administrator.

[FR Doc. 98-24621 Filed 9-14-98; 8:45 am]

BILLING CODE 4410-09-M

NUCLEAR REGULATORY COMMISSION

[Docket No. 50-260 and 50-296]

Tennessee Valley Authority; Notice of Issuance of Amendment to Facility Operating License

The U.S. Nuclear Regulatory Commission (NRC, the Commission) has issued Amendment Nos. 254 and 214 to Facility Operating License Nos. DPR-52 and DPR-68 issued to the Tennessee Valley Authority (TVA or the licensee) for operation of the Browns Ferry Nuclear Plant (BFN), Units 2 and 3, respectively, located in Limestone County, Alabama.

The amendments allow operation of BFN Units 2 and 3 at 3458 Megawatts thermal and approve changes to the TS to implement uprated power operation. The application for the amendments complies with the standards and requirements of the Atomic Energy Act of 1954, as amended (the Act) and the Commission's rules and regulations. The Commission has made appropriate findings as required by the Act and the Commission's rules and regulations in 10 CFR Chapter I, which are set forth in the license amendments.

Notices of Consideration of Issuance of Amendments to facility Operating License and Opportunity for Hearing in connection with this action were published in the **Federal Register** on June 9, 1998 (63 FR 31533), and July 28, 1998 (63 FR 40323). The licensee provided additional details by letters dated March 20, May 22, June 12 and 17, and July 24 and 31, and September 1, 1998, which did not affect the staff's proposed action described in the above-cited FR notices. No request for a hearing or petition for leave to intervene was filed following these notices.

The Commission has prepared an environmental assessment of the action and has determined not to prepare an environmental impact statement. Based upon the environmental assessment, the Commission has concluded that the issuance of the amendments will not have a significant impact on the quality of the human environment (63 FR 46491).

The Acting Deputy Administrator further orders that aggregate production quotas for all other Schedules I and II controlled substances included in Sections 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations remain at zero.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Acting Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations.

Aggregate production quotas apply to approximately 200 DEA registered bulk and dosage form manufacturers of Schedules I and II controlled substances. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor